A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (NCT07455383)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 302)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Who can join: Review the eligibility criteria below.
Location: Alkermes Investigational Site — Cullman, Alabama
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- Alkermes Investigational Site — Cullman, Alabama
- Alkermes Investigational Site — Phoenix, Arizona
- Alkermes Investigational Site — Los Angeles, California
- Alkermes Investigational Site — Boulder, Colorado
- Alkermes Investigational Site — Brandon, Florida
- Alkermes Investigational Site — Miami, Florida
- Alkermes Investigational Site — Winter Park, Florida
- Alkermes Investigational Site — Macon, Georgia
- Alkermes Investigational Site — Kansas City, Kansas
- Alkermes Investigational Site — Newton, Massachusetts
- Alkermes Investigational Site — Lansing, Michigan
- Alkermes Investigational Site — St Louis, Missouri
- Alkermes Investigational Site — Middletown, New Jersey
- Alkermes Investigational Site — Charlotte, North Carolina
- Alkermes Investigational Site — Cincinnati, Ohio
- Alkermes Investigational Site — Wyomissing, Pennsylvania
- Alkermes Investigational Site — Columbia, South Carolina
- Alkermes Investigational Site — Austin, Texas
- Alkermes Investigational Site — San Antonio, Texas
- Alkermes Investigational Site — Sugar Land, Texas
- Alkermes Investigational Site — Macquarie Park, New South Wales
- Alkermes Investigational Site — Namur,
- Alkermes Investigational Site — Markham, Ontario
- Alkermes Investigational Site — Toronto, Ontario
- Alkermes Investigational Site — Bordeaux,
📞 Contact the Study Coordinator
Phone: (888) 235-8008
Email: clinicaltrials@alkermes.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Narcolepsy Type 1
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia — Cullman, Alabama
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Auburn, Alabama
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Auburn, Alabama
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) — Miami, Florida
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence — Colorado Springs, Colorado
Explore by condition: All Narcolepsy Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.